Associate Surgeon, Brigham and Women’s Hospital
Assistant Professor of Surgery, Harvard Medical School
Director, Neurosurgical Pain Management Program, Brigham and Women’s Hospital
Director, Johnson Laboratory, Brigham and Women’s Hospital
Medical Education:
Harvard Medical School, 1995
Internship:
General Surgery, University of Washington School of Medicine, 1996
Residency:
Neurosurgery, University of Washington School of Medicine, 2003
Fellowship:
Neurosurgery, Oregon Health & Sciences University,
Clinical Interests:
Brain tumors, neurosurgical oncology, neurosurgical pain management.
Mark D. Johnson was born in 1964 in Memphis, Tennessee. At the age of 14, he received a scholarship to attend Phillips Exeter Academy in Exeter, New Hampshire, where he graduated with honors in 1982. He subsequently graduated Magna Cum Laude with a degree in chemistry from Amherst College in 1986. Dr. Johnson then matriculated at Harvard Medical School, where he earned a medical degree and a Ph.D. in neurobiology in 1995. He completed an internship in general surgery and a residency in neurosurgery at the University of Washington in Seattle in 2003. While at the University of Washington, Dr. Johnson also performed postdoctoral research on mechanisms of neuronal cell death occurring after injury. He received an NIH postdoctoral National Research Service Award and, after his appointment as Acting Instructor at the University of Washington in 2003, he was also awarded an NIH K08 Research Award to support his work.
Upon completion of his residency, Dr. Johnson returned to Boston to join the Department of Neurosurgery at Brigham and Women’s Hospital and Harvard Medical School as an Assistant Professor. Dr. Johnson’s clinical interests include neuro-oncology and the neurosurgical management of pain. He maintains an independent laboratory that is focused on the cellular and molecular biology of brain tumors. He currently resides in the Boston area with his wife and children.
Publications:
Yang HW, Menon L, Black PM, Carroll RS and Johnson MD. SNAI2/Slug promotes growth and invasion in human gliomas. BMC Cancer 2010; 10:301. PMID:20565806
Dreyfuss JM, Johnson MD, Park PJ. Meta-analysis of glioblastoma multiforme versus anaplastic astrocytoma identifies robust gene markers. Mol Cancer 2009; 8:71. PMID:19732454
Kim H, Huang W, Jiang X, Pennicooke B, Park PJ, Johnson MD. Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship. Proc Natl Acad Sci 2010; 107:2183-2188. PMID:20080666
Jiang X, Yu Y, Yang HW, Agar N, Frado L, Johnson MD. The imprinted gene PEG3 inhibits Wnt signaling to regulate glioma growth. J Biol Chem 2010; 285:8472-8480. PMID:20064927
Agar NY, Malcolm JG, Mohan V, Yang HW, Johnson MD, Tannenbaum A, Agar JN, Black PM. Imaging of Meningioma Progression by Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry. Anal Chem 2010; 82:2621-2625. PMID: 20196536
Kim T, Huang W, Park R, Park PJ and Johnson MD. A developmental taxonomy of glioblastoma defined and maintained by microRNAs. Cancer Res 2011; 71(9):3387-99. PMID:20064927
Xi R, Hadjipanayis AG, Luquette LJ, Kim TM, Lee E, Zhang J, Johnson MD, Muzny DM, Wheeler DA, Gibbs RA, Kucherlapati R, Park PJ. Copy number variation detection in whole-genome sequencing data using the Bayesian information criterion. Proc Natl Acad Sci USA 2011; 108:E1128-1136. PMID: 22065754
Lin N, Dunn IF, Glantz M, Allison DL, Jensen R, Johnson MD, Friedlander RM, Kesari S. Benefit of ventriculoperitoneal cerebrospinal fluid shunting and intrathecal chemotherapy in neoplastic meningitis: a retrospective, case-controlled study. J Neurosurg 2011; 115:730-736. PMID: 21721878
Yang HW, Kim T-M, Song S, Shrinath N, Park R, Kalamarides M, Park PJ, Black PM, Carroll RS and Johnson MD. Alternative splicing of CHEK2 and co-deletion with NF2 promote chromosomal instability in meningioma. Neoplasia 2012; 14:20-28. (Cover Feature) PMID: 22355270
Jiang X, Xing H, Kim T-M, Jung Y, Huang W, Yang HW, Song S, Park PJ, Carroll RS and Johnson MD. Numb regulates glioma stem cell fate and growth by altering epidermal growth factor receptor and SCF ubiquitin ligase activity. Stem Cells 2012 Stem Cells. 2012; 30:1313-26. PMID: 22553175
Kim TM, Xi R, Luquette LJ. Park RW, Johnson MD and Peter J. Park. Functional genomic analysis of chromosomal aberrations in a compendium of 8000 cancer genomes. Genome Res 2012